| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = -$29 ) |
| | 2023 | 2021 | TRIURSUS THERAPEUTICS INCORPORATED | 3308 ADELAIDE WAY | BELMONT | CA | 94002-1224 | SAN MATEO | USA | R44CA250639 | TIM-1 blocking mAbs for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation patients | 000 | 1 | NIH | 4/28/2023 | -$29 |
|
| Issue Date FY: 2021 ( Subtotal = $52,000 ) |
| | 2021 | 2021 | TRIURSUS THERAPEUTICS INCORPORATED | 3308 ADELAIDE WAY | BELMONT | CA | 94002-1224 | SAN MATEO | USA | R44CA250639 | TIM-1 blocking mAbs for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation patients | 000 | 1 | NIH | 3/3/2021 | $52,000 |
|
| Issue Date FY: 2020 ( Subtotal = $399,715 ) |
| | 2020 | 2020 | TRIURSUS THERAPEUTICS INCORPORATED | 3308 ADELAIDE WAY | BELMONT | CA | 94002-1224 | SAN MATEO | USA | R44CA250639 | TIM-1 blocking mAbs for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation patients | 000 | 1 | NIH | 9/9/2020 | $399,715 |
|
|
